Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 20/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 0.81 |
| ▸ | MMP3 | P08254 | 2/20 | 0.81 |
| ▸ | MMP9 | P14780 | 2/20 | 0.81 |
| ▸ | MMP8 | P22894 | 2/20 | 0.81 |
| ▸ | MMP12 | P39900 | 1/20 | 0.81 |
| ▸ | MMP14 | P50281 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208142 | 0.93 | MMP1 (0.87) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL14188830 | 0.89 | MMP1 (0.83) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL25304 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL24724 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6951011 | 0.88 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7213003 | 0.86 | MMP1 (0.82) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6946809 | 0.85 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL15505961 | 0.84 | MMP1 (0.81) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL135680 | 0.83 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208603 | 0.83 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070058-B1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | claimed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | claimed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | claimed |
| EP-1682113-B1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20070104644-A1 | Inhibitor imaging agents | CUTHBERTSON ALAN | 2007-05-10 | — | — | US | disclosed |
| EP-1070058-B1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070104644-A1 | Inhibitor imaging agents | MMP3, MMP1, MMP10 | MMP1 2/4885MMP13 14/4885MMP2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.